Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in <i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial

<table>Mean SICT domain scores at baseline and EOS for overall <i>β</i>-Thalassemia population.</table>

Anemia

fig3

Figure 3

Figure 3: Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in <i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial 

Figure 3 | Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial 